Live attenuated AIDS viruses as vaccines: Promise or peril?

Immunological Reviews

Volumn 170, Issue , 1999, Pages 135-149

  Ruprecht, Ruth M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

ANIMAL MODEL; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS; PRIMATE; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

AIDS VACCINES; ANIMALS; GENE DELETION; GENES, NEF; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PRIMATES; SAFETY; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED; VIRULENCE;

EID: 0032833225     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01335.x     Document Type: Review

References (72)

1. 1. Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: WB Saunders Company; 1999.
2. 2. Gershon AA, Takahashi M, White CJ. Varicella vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: WB Saunders Company; 1999. p. 475-507.
3. 3. Marthas ML, et al. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 1990;64:3694-3700.
4. 4. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 1990;3:1023-1040.
5. 5. Marthas ML, et al. Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus. J Med Primatol 1989;18:311-319.
6. 6. Marthas ML, et al. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1995;69:4198-4205.
7. 7. Kestler HW, et al. Importance of the nef gene for maintenance of high virus loads and/or development of AIDS. Cell 1991;65:651-662.
8. 8. Daniel MD, Kirchhoff, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the net gene. Science 1992;258:1938-1941.
9. 9. Connor RI, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998;72;7501-7509.
10. 10. Lewis MG, et al. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J Virol 1999;73:1262-1270.
11. 11. Shibata R, Siemon C, Czajak SC, Desrosiers RC, Martin MA. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with human immunodeficiency virus type 1 chimeric virus. J Virol 1997;71:8141-8148.
12. 12. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996;70:3724-3733.
13. 13. Almond N, Kent K, Cranage M, Rud E, Clarke B. Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus infected cells. Lancet 1995;345:1342-1344.
14. 14. Stahl-Hennig C, et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol 1996;77:2969-2981.
15. 15. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R. Protection from pathogenic SIV mac challenge following short-term infection with a nef-deficient attenuated virus. Virology 1996;219:195-205.
16. mac JS challenge within three weeks [abstract 155]. In: Abstract book: 1998 Meeting of the Institute of Human Virology; 1998 Aug 23-29; Baltimore. p.80.
17. 17. Cranage MP, et al. Macaques infected with live attenuated SIVmac are protected against super-infection via the rectal mucosa. Virology 1997;229:143-154.
18. 18. Clements JE, et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
19. 19. Haga T, Kuwata T, Masahiro U, Igarashi T, Miyazaki Y, Hayami M. A new approach to AIDS research and prevention: the use of gene mutated HIV-1 /SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines. Microbiol Immunol 1998;42:245-251.
20. 20. Joag SV, et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J Virol 1998;72:9069-9078.
21. 21. Putkonen P, et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med 1995;1:914-918.
22. 22. Rud EW, et al. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones of containing nef size variants. J Gen Virol 1994;75:529-543.
23. 23. Yu M. Yes it is time to test live attenuated HIV. J NIH Res 1994;6:20.
24. mac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 1994;10:607-616.
25. 25. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825
26. 26. Wyand MS. Manson KH, Lackner A, Desrosiers RC, Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus, Nat Med 1997;3:32-36.
27. 27. Cohen J. Weakened SIV vaccine still kills. Science 1997;278:24-25.
28. 28. Baba TW, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203.
29. 29. Kirchhoff F, Kestler HW III, Desrosiers, RC. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in the absence of an intact nef gene. J Virol 1994;68:2031-2037.
30. 30. Luciw PA, Shaw KE, Shacklett BL, Marthas ML. Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis. Virology 1998;252:9-16.
31. 31. Desrosiers RC, Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. AIDS Res Hum Retroviruses 1994;10:331-332.
32. 32. Johnson RP. Live attenuated AIDS vaccines: hazards and hopes. Nat Med 1999;5:154-155.
33. 33. Luciw PA, Low T, Mandell C, Stout M, Ansari A, Villinger F. Pathogenesis by replication-competent simian immunodeficiency virus (SIV) vector expressing the interleukin-2 gene [abstract 27]. In: Program and abstracts of the 13th Annual Symposium on Nonhuman Primate Models for AIDS; 1995 Nov 5-8; Monterey (CA).
34. 34. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP. Repair and evolution in nef in vivo modulates simian immunodeficiency virus virulence, J Virol 1995;69:5117-5123.
35. 35. Dittmer U, et al. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 1995;212:392-397.
36. 36. Stahl-Hennig C, et al. Attenuated SIV imparts immunity to challenge with pathogenic spleen-derived SIV but cannot prevent repair of the nef deletion. Immunol Lett 1996; 51:129 -135.
37. 37. Baba TW, et al. Technical comments. Attenuated retrovirus vaccines and AIDS. Science 1995;270:1220-1221
38. 38. Ruprecht RM, Baba TW, Rasmussen R, Hu Y, Sharma PL. Murine and simian retrovirus models: the threshold hypothesis. AIDS 1996;10(Suppl A):S33-S40.
39. 39. Ruprecht RM. et al. Live attenuated HIV as a vaccine for AIDS: pros and cons. Semin Virol 1996;7:147-155.
40. 40. Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 1994;10:343-350.
41. 41. Desrosiers R, Daniel M, Lifson J, Arthur LO. Infection of chimpanzees with attenuated HIV-1 deletion mutants. In: Girard M, Dodet B, eds, 10e Colloque des Cents Gardes, Retroviruses of human AIDS and related animal diseases, Amsterdam: Elsevier; 1995. p. 197-200.
42. 42. Deacon NJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
43. 43. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact nef sequences in a long term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-232.
44. 44. Mariani R, et al. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol 1996;70:7752-7764.
45. 45. Learmont J, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992;340:863-867.
46. 46. Deacon NJ, McPhee DA, Crowe S, Learmont J, Mills J, Attenuated HIV vaccine: caveats. Science 1996;271:1791-1792.
47. 47. Cohen J, At conference, hope for success is further attenuated. Science 1994;266:1154.
48. 48. Farthing CF, Sullivan JL. STV vaccine for AIDS. Science 1998;279:14-15.
49. 49. Learmont JC, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1 N Engl J Med 1999;340:1715-1722.
50. 50. Greenough TC, Sullivan JL, Desrosier RC. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 1999;340:236-237.
51. 51. Gibbs JS, et al. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 1995;69:2378-2383.
52. mac251 challenge. AIDS Res Hum Retroviruses 1995;11:1397-1406.
53. 53. Lohman BL, et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 1994; 68:7021-7029.
54. 54. Live-attenuated AIDS vaccines: new safety findings reported. JAVI Report 1997;2:1-3
55. 55. Smith SM. Markham RB. Jeang NT, Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Proc Natl Acad Sci USA 1996;93:7955-7960.
56. 56. Chakrabarti BK, Maitra RK. Ma XZ, Kestler HW. A candidate live inactivatable vaccine for AIDS. Proc Natl Acad Sci USA 1996;93:9810-9815.
57. 57. White CJ. Letter to the editor. Pediatrics 1992;89:354.
58. 58. Sharpe SA, Whatmore AM, Hall GA, Cranage MP. Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus. J Gen Virol 1997;78:1923-1927.
59. 59. Montefiori DC, Baba TW, Li A, Bilska M, Ruprecht RM. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239Δ3 in adult and infant rhesus monkeys. J Immumol 1996;157:5528-5535.
60. 60. Lohman BL, McChesney MB, Miller CJ, Otsyula M. Berardi CJ, Marthas ML, Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques. J Med Primatol 1994; 23:95-101.
61. 61. Johnson RP, et al. Induction of vigorous cytotoxic T lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997;71:7711-7718.
62. 62. Almond N, et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I, Protection cannot be transferred with immune serum. J Gen Virol 1997;78:1919-1922.
63. 63. Langlois AJ, et al. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol 1998;72:6950-6955.
64. 64. Gundlach BR, et al. Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol 1998;72:7846-7851.
65. 65. Cole KS, et al. Evolution of envelope specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
66. 66. Montelaro RC, Cole KS, Hammond SA. Maturation of immune responses to lentivirus infection: implication for AIDS vaccine development. AIDS Res Hum Retroviruses 1998;14 (Suppl 3):S255-S259.
67. 67. Matano T, Shibata R, Siemon C, Connors M, Clifford Lane H, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of SIV/HIV chimeric virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
68. 68. Stebbings R, et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection AIDS Res Hum Retroviruses 1998;14:1187-1198.
69. 69. Ten Haaft P, Verstrepen B, Überla K, Rosenwirth B, Heeney J. A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques. J Virol 1998;72:10281-10285.
70. 70. Rey Cuillé A, et al. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998;72:3872-3886.
71. 71. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151:420-436.
72. 72. Havlir DV, Barnes PF, Tuberculosis in patients with human immunodeficiency virus infection. Curr Concepts 1999;340:367-373.